172 related articles for article (PubMed ID: 29399118)
21. Vitamin E-based redox-sensitive salinomycin prodrug-nanosystem with paclitaxel loaded for cancer targeted and combined chemotherapy.
Liang DS; Liu J; Peng TX; Peng H; Guo F; Zhong HJ
Colloids Surf B Biointerfaces; 2018 Dec; 172():506-516. PubMed ID: 30212688
[TBL] [Abstract][Full Text] [Related]
22. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
[TBL] [Abstract][Full Text] [Related]
23. Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma.
Gao J; Xia Y; Chen H; Yu Y; Song J; Li W; Qian W; Wang H; Dai J; Guo Y
Nanomedicine (Lond); 2014 Feb; 9(2):279-93. PubMed ID: 23721168
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
25. Uncoupling Warburg effect and stemness in CD133
Koka P; Mundre RS; Rangarajan R; Chandramohan Y; Subramanian RK; Dhanasekaran A
Mol Biol Rep; 2018 Dec; 45(6):1653-1662. PubMed ID: 30128626
[TBL] [Abstract][Full Text] [Related]
26. Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies.
Wei J; Sun J; Liu Y
Oncol Lett; 2019 Apr; 17(4):4024-4033. PubMed ID: 30930999
[TBL] [Abstract][Full Text] [Related]
27. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
Huang X; Borgström B; Kempengren S; Persson L; Hegardt C; Strand D; Oredsson S
BMC Cancer; 2016 Feb; 16():145. PubMed ID: 26906175
[TBL] [Abstract][Full Text] [Related]
29. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-24 inhibits the phenotype and tumorigenicity of cancer stem cell in osteosarcoma via downregulation Notch and Wnt/β-catenin signaling.
Zhuo B; Wang X; Shen Y; Li J; Li S; Li Y; Wang R
J Bone Oncol; 2021 Dec; 31():100403. PubMed ID: 34804789
[TBL] [Abstract][Full Text] [Related]
31. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
32. Self-targeted salinomycin-loaded DSPE-PEG-methotrexate nanomicelles for targeting both head and neck squamous cell carcinoma cancer cells and cancer stem cells.
Zhu M; Chen S; Hua L; Zhang C; Chen M; Chen D; Dong Y; Zhang Y; Li M; Song X; Chen H; Zheng H
Nanomedicine (Lond); 2017 Feb; 12(4):295-315. PubMed ID: 28093940
[TBL] [Abstract][Full Text] [Related]
33. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
[TBL] [Abstract][Full Text] [Related]
34. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of lysosomal TRPML1 channel eliminates breast cancer stem cells by triggering ferroptosis.
Fan C; Wu H; Du X; Li C; Zeng W; Qu L; Cang C
Cell Death Discov; 2024 May; 10(1):256. PubMed ID: 38802335
[TBL] [Abstract][Full Text] [Related]
36. TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133
Feng J; Lan R; Cai G; Lin J
Int J Clin Exp Pathol; 2019; 12(4):1134-1153. PubMed ID: 31933929
[TBL] [Abstract][Full Text] [Related]
37. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
38. Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells.
Tsai PH; Wang ML; Chang JH; Yarmishyn AA; Nhi Nguyen PN; Chen W; Chien Y; Huo TI; Mou CY; Chiou SH
ACS Appl Mater Interfaces; 2019 Jun; 11(22):19808-19818. PubMed ID: 31066542
[TBL] [Abstract][Full Text] [Related]
39. Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications.
Wang H; Zhang H; Zhu Y; Wu Z; Cui C; Cai F
Front Oncol; 2021; 11():654428. PubMed ID: 34381705
[TBL] [Abstract][Full Text] [Related]
40. A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent.
Antoszczak M
Eur J Med Chem; 2019 Feb; 164():366-377. PubMed ID: 30611056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
